JP2022531408A5 - - Google Patents
Info
- Publication number
- JP2022531408A5 JP2022531408A5 JP2021565064A JP2021565064A JP2022531408A5 JP 2022531408 A5 JP2022531408 A5 JP 2022531408A5 JP 2021565064 A JP2021565064 A JP 2021565064A JP 2021565064 A JP2021565064 A JP 2021565064A JP 2022531408 A5 JP2022531408 A5 JP 2022531408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- galectin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841732P | 2019-05-01 | 2019-05-01 | |
| US62/841,732 | 2019-05-01 | ||
| PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531408A JP2022531408A (ja) | 2022-07-06 |
| JP2022531408A5 true JP2022531408A5 (https=) | 2023-05-11 |
| JP7581238B2 JP7581238B2 (ja) | 2024-11-12 |
Family
ID=73029403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565064A Active JP7581238B2 (ja) | 2019-05-01 | 2020-05-01 | 抗ガレクチン９抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220185896A1 (https=) |
| EP (1) | EP3962954A4 (https=) |
| JP (1) | JP7581238B2 (https=) |
| CN (2) | CN114026126B (https=) |
| AU (1) | AU2020266677A1 (https=) |
| CA (1) | CA3138863A1 (https=) |
| SG (1) | SG11202112112UA (https=) |
| WO (2) | WO2020223704A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3080120C (en) | 2017-10-27 | 2023-11-21 | New York University | Anti-galectin-9 antibodies and uses thereof |
| JP7581238B2 (ja) * | 2019-05-01 | 2024-11-12 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体およびその使用 |
| WO2022109299A1 (en) * | 2020-11-20 | 2022-05-27 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| CA3217833A1 (en) * | 2021-04-30 | 2022-11-03 | Puretech Lyt, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| US20240190970A1 (en) * | 2021-04-30 | 2024-06-13 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
| MX2024004012A (es) * | 2021-10-01 | 2024-07-01 | Puretech Lyt Inc | Anticuerpos anti-galectina-9 y usos terapéuticos de estos. |
| KR20250029919A (ko) * | 2022-06-29 | 2025-03-05 | 퓨어테크 엘와이티, 아이엔씨. | 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료 |
| CN120585880B (zh) * | 2025-08-07 | 2025-12-09 | 四川大学华西医院 | 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2591786B1 (en) * | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| CN101120021A (zh) * | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CN101977934B (zh) * | 2008-01-18 | 2014-09-17 | 健泰科生物技术公司 | 用于靶向k63连接的多聚遍在蛋白的方法和组合物 |
| MX2011000655A (es) * | 2008-07-18 | 2011-03-21 | Oragenics Inc | Composiciones para la deteccion y tratamiento de cancer colorrectal. |
| WO2012064836A1 (en) * | 2010-11-10 | 2012-05-18 | Genentech, Inc. | Methods and compositions for neural disease immunotherapy |
| CA2820642A1 (en) * | 2010-12-09 | 2012-06-14 | Galpharma Co., Ltd. | Galectin-9-secreting cell, and production method and use of the same |
| FR3021970B1 (fr) | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| US10837966B2 (en) * | 2014-11-04 | 2020-11-17 | Dana-Farber Cancer Institute, Inc. | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses |
| US10294294B2 (en) * | 2015-09-10 | 2019-05-21 | Albert Einstein College Of Medicine | Synthetic antibodies to BAX and uses thereof |
| WO2017202962A1 (en) * | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| CA3066747A1 (en) * | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| WO2019036031A2 (en) * | 2017-08-17 | 2019-02-21 | Nektar Therapeutics | IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT |
| CA3080120C (en) * | 2017-10-27 | 2023-11-21 | New York University | Anti-galectin-9 antibodies and uses thereof |
| AU2020247993A1 (en) * | 2019-03-25 | 2021-11-18 | New York University | Anti-Galectin-9 antibodies and uses thereof |
| JP7581238B2 (ja) * | 2019-05-01 | 2024-11-12 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体およびその使用 |
| US20220332832A1 (en) * | 2019-08-01 | 2022-10-20 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| US20240287195A1 (en) * | 2020-10-26 | 2024-08-29 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma |
| US20240043543A1 (en) * | 2020-11-20 | 2024-02-08 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| WO2022109299A1 (en) * | 2020-11-20 | 2022-05-27 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| CA3217833A1 (en) * | 2021-04-30 | 2022-11-03 | Puretech Lyt, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| US20240190970A1 (en) * | 2021-04-30 | 2024-06-13 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
-
2020
- 2020-05-01 JP JP2021565064A patent/JP7581238B2/ja active Active
- 2020-05-01 EP EP20798582.1A patent/EP3962954A4/en active Pending
- 2020-05-01 CN CN202080047488.7A patent/CN114026126B/zh active Active
- 2020-05-01 WO PCT/US2020/031184 patent/WO2020223704A1/en not_active Ceased
- 2020-05-01 US US17/607,878 patent/US20220185896A1/en not_active Abandoned
- 2020-05-01 CN CN202411238025.5A patent/CN119033928A/zh active Pending
- 2020-05-01 SG SG11202112112UA patent/SG11202112112UA/en unknown
- 2020-05-01 CA CA3138863A patent/CA3138863A1/en active Pending
- 2020-05-01 AU AU2020266677A patent/AU2020266677A1/en active Pending
- 2020-05-01 US US17/607,879 patent/US20220178930A1/en not_active Abandoned
- 2020-05-01 WO PCT/US2020/031181 patent/WO2020223702A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531408A5 (https=) | ||
| JP2023130496A (ja) | 癌治療のための併用療法 | |
| JP2020508317A5 (https=) | ||
| JP2018522850A5 (https=) | ||
| JP2016530323A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2003531129A5 (https=) | ||
| RS67037B1 (sr) | Lečenje kancera pluća korišćenjem kombinacije anti‑pd‑1 antitela i anti‑ctla‑4 antitela | |
| JP2020529469A5 (https=) | ||
| O'Donnell et al. | Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 | |
| AU2015265859A1 (en) | Antagonists of PDL-1 and PD-1 for the treatment of HPV-negative cancers | |
| JP2023551559A5 (https=) | ||
| WO2017091429A1 (en) | Combination therapy for cancer | |
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| JP2020507596A5 (https=) | ||
| JP2023539625A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2015528802A5 (https=) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| JP2024540435A5 (https=) | ||
| AU2022318734A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2022534494A5 (https=) | ||
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |